Business
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
New report adds to growing evidence of iNKT cell therapy’s potential in solid tumorsNEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the publication of another landmark case in Nature’s Oncogene describing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer, following
About this update from Agenus Inc.
[{"type":"image","alt":"MiNK Therapeutics","displaySize":"","headline":null,"caption":"MiNK Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zvDa2P.MLQrfKYIZ2UPPSQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645","width":300,"height":116}},"lazy":false},{"type":"text","content":"New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors","length":84,"tagName":"p"},{"type":"text","content":"NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the publication of another landmark case in Nature’s Oncogene describing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer, following treatment with agenT-797, MiNK’s allogeneic iNKT cell therapy.","length":478,"tagName":"p"},{"type":"text","content":"Complete remission after failure on platinum-based chemotherapy, autologous stem cell transplant, and multiple ICIs (anti–PD-1, anti–CTLA-4, and anti–TIGIT)","length":156,"tagName":"p"},{"type":"text","content":"The publication, titled “Salvage therapy with allogeneic invariant natural killer T cells in a heavily pre-treated germ cell tumor,” presents a patient case from MiNK’s clinical trial (NCT05108623). The patient had progressed after multiple lines of therapy—including platinum-based chemotherapy, autologous stem cell transplant, and multiple immune checkpoint inhibitors (anti–PD-1, anti–CTLA-4, and anti–TIGIT)—and received a single infusion of agenT-797 alongside nivolumab. The patient achieved a complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later. Donor iNKT cells were detectable up to six months post-infusion, and treatment was well-tolerated with no cytokine release syndrome (CRS) or graft-versus-host disease (GVHD).","length":783,"tagName":"p"},{"type":"text","content":"“This case exemplifies the powerful potential of iNKT cells in treating even the most challenging cancers,” said Dr. Ben...